Northern Trust Corp Catalyst Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,383,800 shares of CPRX stock, worth $31.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,383,800

Previous 1,386,707 0.21%

Holding current value

$31.4 Million

Previous $21.5 Million 28.07%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$15.19 - $21.35 $44,157 - $62,064	-2,907 Reduced 0.21%	1,383,800 $27.5 Million
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $631,841 - $728,253	-43,041 Reduced 3.01%	1,386,707 $21.5 Million
Q1 2024 May 14, 2024	BUY	$13.18 - $17.11 $145,072 - $188,329	11,007 Added 0.78%	1,429,748 $22.8 Million
Q4 2023 Feb 13, 2024	SELL	$11.78 - $17.29 $217,034 - $318,550	-18,424 Reduced 1.28%	1,418,741 $23.8 Million
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $353,762 - $454,535	30,262 Added 2.15%	1,437,165 $16.8 Million
Q2 2023 Aug 11, 2023	BUY	$11.5 - $18.08 $163,852 - $257,603	14,248 Added 1.02%	1,406,903 $18.9 Million
Q1 2023 May 15, 2023	SELL	$14.34 - $21.05 $23,790 - $34,921	-1,659 Reduced 0.12%	1,392,655 $23.1 Million
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $336,299 - $535,333	27,453 Added 2.01%	1,394,314 $25.9 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $358,146 - $787,314	50,729 Added 3.85%	1,366,861 $17.5 Million
Q2 2022 Aug 12, 2022	SELL	$6.23 - $8.57 $23,431 - $32,231	-3,761 Reduced 0.28%	1,316,132 $9.23 Million
Q1 2022 May 13, 2022	SELL	$5.31 - $8.31 $310,884 - $486,525	-58,547 Reduced 4.25%	1,319,893 $10.9 Million
Q4 2021 Feb 08, 2022	SELL	$5.21 - $7.45 $246,240 - $352,109	-47,263 Reduced 3.32%	1,378,440 $9.33 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $7,541 - $9,392	1,555 Added 0.11%	1,425,703 $7.56 Million
Q2 2021 Aug 13, 2021	BUY	$4.29 - $6.05 $1.07 Million - $1.51 Million	249,975 Added 21.29%	1,424,148 $8.19 Million
Q1 2021 May 12, 2021	SELL	$3.45 - $4.69 $269,679 - $366,607	-78,168 Reduced 6.24%	1,174,173 $5.41 Million
Q4 2020 Feb 11, 2021	SELL	$2.97 - $3.83 $229,551 - $296,020	-77,290 Reduced 5.81%	1,252,341 $4.18 Million
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $145,734 - $249,270	-49,069 Reduced 3.56%	1,329,631 $3.95 Million
Q2 2020 Aug 14, 2020	BUY	$3.48 - $5.05 $514,124 - $746,071	147,737 Added 12.0%	1,378,700 $6.37 Million
Q1 2020 May 14, 2020	SELL	$2.61 - $5.21 $12,940 - $25,831	-4,958 Reduced 0.4%	1,230,963 $4.74 Million
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $165,183 - $256,551	45,009 Added 3.78%	1,235,921 $4.63 Million
Q3 2019 Nov 13, 2019	BUY	$3.89 - $7.43 $129,031 - $246,453	33,170 Added 2.87%	1,190,912 $6.32 Million
Q2 2019 Aug 13, 2019	BUY	$2.7 - $6.11 $82,074 - $185,731	30,398 Added 2.7%	1,157,742 $4.44 Million
Q1 2019 May 13, 2019	SELL	$2.11 - $5.33 $2,736 - $6,913	-1,297 Reduced 0.11%	1,127,344 $5.75 Million
Q4 2018 Feb 12, 2019	SELL	$1.92 - $3.62 $49,338 - $93,023	-25,697 Reduced 2.23%	1,128,641 $2.17 Million
Q3 2018 Nov 14, 2018	BUY	$2.81 - $3.78 $130,367 - $175,369	46,394 Added 4.19%	1,154,338 $4.36 Million
Q2 2018 Sep 18, 2018	SELL	$2.26 - $3.84 $15,044 - $25,562	-6,657 Reduced 0.6%	1,107,944 $3.46 Million
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $236,518 - $401,871	104,654 Added 10.36%	1,114,601 $3.48 Million
Q1 2018 May 09, 2018	BUY	$2.39 - $4.01 $443,677 - $744,412	185,639 Added 22.52%	1,009,947 $2.41 Million
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $32,115 - $56,298	12,795 Added 1.58%	824,308 $3.22 Million
Q3 2017 Nov 13, 2017	BUY	$2.4 - $2.94 $1.95 Million - $2.39 Million	811,513	811,513 $2.05 Million

Others Institutions Holding CPRX

# of Institutions

327

Shares Held

94.1M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.33B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Catalyst Pharmaceuticals, Inc. Transaction History